bio chat
“MedTech industry in India awaiting to
unleash its potential”
In a chat with the BioVoice, Mr Rajiv Nath, Forum Coordinator, Association of
Indian Medical Devices Industry (AiMeD), the apex body representing domestic
medical devices manufacturers, spoke extensively on various issues concerning
Indian medical technology industry. Read the detailed interview below:
BY RAHUL KOUL
How do you view the recent move by the
government to put a price cap on imported
stents? Are the Indian stents really of the
matching quality?
The long awaited move of government to step in to
control the high prices of cardiac stents shall bring
relief for many poor patients for whom the cost of
affording a drug eluting stent (DES) had become
prohibitive. A correction and price regulation in this
market was long overdue and AiMeD supports
government’s move to finally put a cap on the MRP’s
which shall ensure fair practices in this important
sector which was plagued with exorbitant prices
charged from ignorant helpless patients.
Current Indian Market is around 5.50 lakh Stents
per annum out of which more than 90 percent are
DES. The market is growing at a speed of around 15
percent every year and shall become the second
largest market in the World after China by 2020.
Drug Eluting Stents were launched in 2001 by US
multinationals who ruled the market with more than
85 percent share until 2010 when Indian DES
started getting acceptability.
There was a general perception since last 10-15 years
that that American Stents have better quality
standards based on the clinical trials performed and
thus they command a higher price. However, there
are several Indian companies which have done
extensive efforts to create Indian Drug Eluting
Stents which have proven equivalent and even better
than American DES in Large Clinical Studies
(Randomized control trials where Indian DES is
compared with American DES for its clinical
performance and quality Standards). The clinical
data of these Proven Indian DES with high quality
standards have been audited and published by Top
Journals of Cardiology worldwide.
26
BioVoiceNews | September 2016
“
There was a general
perception since last 10-15
years that that American Stents
have better quality standards based
on the clinical trials performed and
thus they command a higher price.
However, there are several Indian
companies which have done
extensive efforts to create Indian
Drug Eluting Stents which have
proven equivalent and even better.